Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPHIRA 2: GLPG1837 in Cystic Fibrosis with S1251N Mutation
NCT02690519Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of GLPG1837 in cystic fibrosis (CF), sponsored by Galapagos NV. Started Jan 2016; status: completed.
02
Drugs
GLPG1837
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02690519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690519.